Last updated: 20 days ago
AstraZeneca's Form 6-K: Tezspire Approved for Chronic Rhinosinusitis Treatment
AstraZeneca's report highlights Tezspire's EU approval for CRSwNP, showcasing significant trial results and market potential. A game-changer for 320M affected globally.